41.
A goose named Lindholm
by Lindholm, Lars H
The Lancet (British edition), 2002-05-18, Vol.359 (9319), p.1720-1720
42.
What are the odds at ASCOT today?
by Lindholm, Lars H
The Lancet (British edition), 2003, Vol.361 (9364), p.1144-1145
43.
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left...
by Devereux, Richard B
Current medical research and opinion, 2007-02, Vol.23 (2), p.259-270
44.
Uses of error : A goose named Lindholm
by Lindholm, Lars H
The Lancet (British edition), 2002-05-18, Vol.359 (9319), p.1720
46.
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
by Lindholm, Lars H
The Lancet (British edition), 2002-06-22, Vol.359 (9324), p.2203-2204
47.
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
by Dahlöf, Björn
The Lancet (British edition), 2002-06-22, Vol.359 (9324), p.2203-2203
48.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
by Hansson, Lennart
The Lancet (British edition), 1999, Vol.354 (9192), p.1751-1756
49.
The STOP-hypertension-2 study
by Lindholm, Lars H
American journal of hypertension, 2000, Vol.13 (4), p.325A-332A
50.
OR-60: Long-term metabolic effects of a candesartan vs hydrochlorothiazide based antihypertensive treatment: Results of the alpine study
by Lindholm, Lars H.
American journal of hypertension, 2003-05, Vol.16 (S1), p.27A-27A
51.
Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study
by Wiik, Benedicte P.
American journal of hypertension, 2010-08, Vol.23 (8), p.845-851
52.
An endothelin antagonist for resistant hypertension – Authors' reply
by Weber, Michael A
The Lancet (British edition), 2010, Vol.375 (9715), p.636-637
53.
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
by Poole-Wilson, Philip A
The Lancet (British edition), 2002-06-22, Vol.359 (9324), p.2199-2199
54.
Valsartan treatment of hypertension--does VALUE add value?
by Lindholm, Lars H
The Lancet (British edition), 2004-06-19, Vol.364 (9426), p.2010
55.
P-329: 1999 WHO/ISH risk stratification for hypertension applied to the 1999 MONICA-sample from Northern Sweden
by Persson, Mats R.
American journal of hypertension, 2001-04, Vol.14 (S1), p.138A-139A
56.
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
by Dahlöf, B
The Lancet (British edition), 1991, Vol.338 (8778), p.1281-1285
57.
An endothelin antagonist for resistant hypertension
by O'Brien, Eoin
The Lancet (British edition), 2010-02-20, Vol.375 (9715), p.636; author reply 636
58.
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Commentary
by LINDHOLM, Lars H
The Lancet (British edition), 2003, Vol.361 (9374), p.2005-2016
59.
O-30: Predictors of cardiovascular events in 9,194 hypertensive patients with left ventricular hypertrophy. The LIFE study
by Kjeldsen, Sverre E.
American journal of hypertension, 2001-04, Vol.14 (S1), p.14A-14A
60.
An endothelin antagonist for resistant hypertension/Authors' reply
by Neeraj Dhaun
The Lancet (British edition), 2010-02-20, Vol.375 (9715), p.635
